NAMS Overview
Upcoming Projects (NAMS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (NAMS)
-
A Third View: Discussing NewAmsterdam Pharma's announcement of Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies on Obicetrapib for Treatment of Dyslipidemia
Ticker: NAMS
Executed On: May 28, 2025 at 10:00 AM EDT -
A Second View: Discussing NewAmsterdam Pharma's announcement of Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies on Obicetrapib for Treatment of Dyslipidemia
Ticker: NAMS
Executed On: May 27, 2025 at 01:30 PM EDT -
Discussing NewAmsterdam Pharma's announcement of Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies on Obicetrapib for Treatment of Dyslipidemia
Ticker: NAMS
Executed On: May 22, 2025 at 04:00 PM EDT -
A Second View: Looking at the current standard of care and the potential of Obicetrapib from NewAmstredam Pharma for the treatment of HeFH from the BROOKLYN, TANDEM and BROADWAY trials
Ticker: NAMS
Executed On: Jan 08, 2025 at 12:00 PM EST -
Looking at the current standard of care and the potential of Obicetrapib from NewAmstredam Pharma for the treatment of HeFH from the BROOKLYN, TANDEM and BROADWAY trials
Ticker: NAMS
Executed On: Dec 30, 2024 at 03:00 PM EST -
A Second View: Looking at the current standard of care and the potential of Obicetrapib from NewAmstredam Pharma for the treatment of HeFH
Ticker: NAMS
Executed On: Nov 13, 2024 at 12:00 PM EST -
Looking at the current standard of care and the potential of Obicetrapib from NewAmstredam Pharma for the treatment of HeFH
Ticker: NAMS
Executed On: Aug 29, 2024 at 03:00 PM EDT -
A Third View: Delving into the recent data from the ROSE2 clinical trial on obicetrapid by NewAmsterdam Pharma for the treatment of Heart Disease.
Ticker: NAMS
Executed On: Feb 27, 2023 at 11:00 AM EST -
A Second View: Delving into the recent data from the ROSE2 clinical trial on obicetrapid by NewAmsterdam Pharma for the treatment of Heart Disease.
Ticker: NAMS
Executed On: Feb 09, 2023 at 03:00 PM EST -
Delving into the recent data from the ROSE2 clinical trial on obicetrapid by NewAmsterdam Pharma for the treatment of Heart Disease.
Ticker: NAMS
Executed On: Feb 06, 2023 at 04:00 PM EST
Upcoming & Overdue Catalysts (NAMS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (NAMS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
